We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y
Read MoreHide Full Article
Fresenius Medical Care AG & Co. KGaA (FMS - Free Report) reported fourth-quarter 2021 adjusted earnings per share (EPS) of $1.03 per share, which beat the Zacks Consensus Estimate of 50 cents. The bottom line increased 35.5% year over year.
Revenue Details
Revenues improved 1.3% year over year to $5.31 billion but missed the Zacks Consensus Estimate by 1.2%.
Segmental Details
In the fourth quarter, Fresenius Medical reported through two segments — Health Care Services and Health Care Products.
Health Care Services revenues rose 6% on a year-over-year basis and 3% at constant currency (cc). The company experienced organic growth in the quarter under review despite the COVID-19 pandemic and lower reimbursement for calcimimetics.
Health Care Products revenues increased 3% on a year-over-year basis and 1% at cc. An increase in sales of machines for chronic treatment, home hemodialysis products and in-center disposables and favorable exchange rate effects contributed to the improvement. However, a decline in sales of products for acute care treatments partially offset the upside.
Geographical Growth
North America
Revenues in the region rose 6% on a year-over-year basis and 1% at cc. On an organic basis, sales in the region remained flat.
EMEA
Revenues in this region increased 2% on a year-over-year basis and 2% at cc in the quarter under review. On an organic basis, sales in the region rose 2%.
Fresenius Medical Care AG & Co. KGaA Price, Consensus and EPS Surprise
Revenues in this region advanced 7% year over year and 5% at cc in the reported quarter. On an organic basis, sales in the region rose 4%.
Latin America
Revenues in Latin America climbed 10% year over year and 17% at cc. Organic growth in the region was 20%.
Guidance
Based on Fresenius Medical’s present projections, the company confirmed its 2022 outlook. The company anticipates both net income and revenues to grow at a low-to-mid-single digit percentage rate.
Summing Up
Fresenius Medical exited the fourth quarter on a mixed note. The company benefited from revenue growth across North America, EMEA, Asia Pacific and Latin America regions. Strength in both Health Care Services and Health Care Products businesses in the quarter under review is encouraging.
However, the company saw business development being substantially impacted by COVID-19 in 2021, the effects of which are anticipated to continue into 2022. During the quarter under review, the company witnessed a decline in excess mortality. The company faces intense competition in the field of health care services and the sale of dialysis products, which remains a concern.
Zacks Rank
The company has a Zacks Rank #3 (Hold).
Earnings of Other MedTech Majors at a Glance
Some better-ranked stocks in the broader medical space that have announced quarterly results are Henry Schein, Inc. (HSIC - Free Report) , Molina Healthcare, Inc. (MOH - Free Report) and Bio-Rad Laboratories, Inc. (BIO - Free Report) .
Henry Schein, carrying a Zacks Rank #1 (Strong Buy), reported fourth-quarter 2021 adjusted earnings of $1.07 per share, which beat the Zacks Consensus Estimate by 18.9%. Revenues of $3.33 billion outpaced the consensus mark by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC surpassed earnings estimates in each of the trailing four quarters, the average surprise being 25.5%.
Molina Healthcare reported fourth-quarter 2021 adjusted EPS of $2.88, which surpassed the Zacks Consensus Estimate by 2.1%. Fourth-quarter revenues of $7.41 billion outpaced the Zacks Consensus Estimate by 3.9%. It currently carries a Zacks Rank #2.
Molina Healthcare has an estimated long-term growth rate of 18.8%. MOH surpassed earnings estimates in three of the trailing four quarters and missed once, the average surprise being 5%.
Bio-Rad reported fourth-quarter 2021 adjusted EPS of $3.21, which surpassed the Zacks Consensus Estimate by 11.9%. Fourth-quarter revenues of $732.8 million outpaced the Zacks Consensus Estimate by 0.5%. It currently has a Zacks Rank #2.
Bio-Rad has an earnings yield of 2.3%, which compares favorably with the industry’s negative yield. BIO surpassed earnings estimates in each of the trailing four quarters, the average surprise being 66.9%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y
Fresenius Medical Care AG & Co. KGaA (FMS - Free Report) reported fourth-quarter 2021 adjusted earnings per share (EPS) of $1.03 per share, which beat the Zacks Consensus Estimate of 50 cents. The bottom line increased 35.5% year over year.
Revenue Details
Revenues improved 1.3% year over year to $5.31 billion but missed the Zacks Consensus Estimate by 1.2%.
Segmental Details
In the fourth quarter, Fresenius Medical reported through two segments — Health Care Services and Health Care Products.
Health Care Services revenues rose 6% on a year-over-year basis and 3% at constant currency (cc). The company experienced organic growth in the quarter under review despite the COVID-19 pandemic and lower reimbursement for calcimimetics.
Health Care Products revenues increased 3% on a year-over-year basis and 1% at cc. An increase in sales of machines for chronic treatment, home hemodialysis products and in-center disposables and favorable exchange rate effects contributed to the improvement. However, a decline in sales of products for acute care treatments partially offset the upside.
Geographical Growth
North America
Revenues in the region rose 6% on a year-over-year basis and 1% at cc. On an organic basis, sales in the region remained flat.
EMEA
Revenues in this region increased 2% on a year-over-year basis and 2% at cc in the quarter under review. On an organic basis, sales in the region rose 2%.
Fresenius Medical Care AG & Co. KGaA Price, Consensus and EPS Surprise
Fresenius Medical Care AG & Co. KGaA price-consensus-eps-surprise-chart | Fresenius Medical Care AG & Co. KGaA Quote
Asia-Pacific
Revenues in this region advanced 7% year over year and 5% at cc in the reported quarter. On an organic basis, sales in the region rose 4%.
Latin America
Revenues in Latin America climbed 10% year over year and 17% at cc. Organic growth in the region was 20%.
Guidance
Based on Fresenius Medical’s present projections, the company confirmed its 2022 outlook. The company anticipates both net income and revenues to grow at a low-to-mid-single digit percentage rate.
Summing Up
Fresenius Medical exited the fourth quarter on a mixed note. The company benefited from revenue growth across North America, EMEA, Asia Pacific and Latin America regions. Strength in both Health Care Services and Health Care Products businesses in the quarter under review is encouraging.
However, the company saw business development being substantially impacted by COVID-19 in 2021, the effects of which are anticipated to continue into 2022. During the quarter under review, the company witnessed a decline in excess mortality. The company faces intense competition in the field of health care services and the sale of dialysis products, which remains a concern.
Zacks Rank
The company has a Zacks Rank #3 (Hold).
Earnings of Other MedTech Majors at a Glance
Some better-ranked stocks in the broader medical space that have announced quarterly results are Henry Schein, Inc. (HSIC - Free Report) , Molina Healthcare, Inc. (MOH - Free Report) and Bio-Rad Laboratories, Inc. (BIO - Free Report) .
Henry Schein, carrying a Zacks Rank #1 (Strong Buy), reported fourth-quarter 2021 adjusted earnings of $1.07 per share, which beat the Zacks Consensus Estimate by 18.9%. Revenues of $3.33 billion outpaced the consensus mark by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC surpassed earnings estimates in each of the trailing four quarters, the average surprise being 25.5%.
Molina Healthcare reported fourth-quarter 2021 adjusted EPS of $2.88, which surpassed the Zacks Consensus Estimate by 2.1%. Fourth-quarter revenues of $7.41 billion outpaced the Zacks Consensus Estimate by 3.9%. It currently carries a Zacks Rank #2.
Molina Healthcare has an estimated long-term growth rate of 18.8%. MOH surpassed earnings estimates in three of the trailing four quarters and missed once, the average surprise being 5%.
Bio-Rad reported fourth-quarter 2021 adjusted EPS of $3.21, which surpassed the Zacks Consensus Estimate by 11.9%. Fourth-quarter revenues of $732.8 million outpaced the Zacks Consensus Estimate by 0.5%. It currently has a Zacks Rank #2.
Bio-Rad has an earnings yield of 2.3%, which compares favorably with the industry’s negative yield. BIO surpassed earnings estimates in each of the trailing four quarters, the average surprise being 66.9%.